Founded in 2020, TYBR Health is a medical device and regenerative medicine company focused on improving surgical recovery. Headquartered in Houston, Texas, TYBR develops solutions that help surgeons protect healing tissues and preserve function after surgery. Its lead product, the B3 GEL™ System, is a bioresorbable gel barrier cleared by the FDA to aid in the protection of soft tissues during post-surgical healing. TYBR is targeting a significant unmet need in musculoskeletal surgery, where recovery complications impact function and healthcare costs. With FDA clearance secured, manufacturing in place, and a proprietary delivery system developed for precise, intraoperative use, TYBR is preparing for commercial launch in late 2025.